Complete Filing Data
Inhibrx Biosciences, Inc. reported Stockholders Equity of $7.99 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Inhibrx Biosciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$140.1M | $1.69B | -$241.4M |
| Research And Development Expense | $113.0M | $203.7M | $191.6M |
| Other Nonoperating Income Expense | -$381.0K | $75.0K | -$580.0K |
| Operating Income Loss | -$135.0M | -$331.4M | -$219.2M |
| Operating Expenses | $136.3M | $331.6M | $221.0M |
| Nonoperating Income Expense | -$5.0M | $2.02B | -$20.5M |
| Interest Income Nonoperating | $7.5M | $10.9M | $11.9M |
| Interest Expense Nonoperating | $12.2M | $13.5M | $31.8M |
| Income Tax Expense Benefit | $2.0K | $2.0K | $3.0K |
| General And Administrative Expense | $23.3M | $127.9M | $29.4M |
| Revenues | $1.3M | $200.0K | $1.8M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$140.1M | $1.69B | |
| Income Taxes Paid Net | $2.0K | $2.0K | $3.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$35.3M | -$28.7M | -$43.3M | -$43.9M | $1.86B | -$78.7M | -$51.8M | -$47.1M | -$48.9M |
| Research And Development Expense | $28.5M | $22.3M | $36.9M | $38.9M | $67.6M | $63.9M | $38.1M | $34.1M | |
| Other Nonoperating Income Expense | -$46.0K | -$246.0K | -$50.0K | $41.0K | $33.0K | -$59.0K | -$135.0K | -$217.0K | |
| Operating Income Loss | -$33.8M | -$27.4M | -$42.9M | -$46.8M | -$160.9M | -$73.8M | -$45.8M | -$41.3M | |
| Operating Expenses | $33.8M | $28.7M | $42.9M | $46.8M | $161.0M | $73.8M | $45.9M | $41.4M | |
| Nonoperating Income Expense | -$1.4M | -$1.3M | -$410.0K | $2.9M | $2.02B | -$4.9M | -$6.0M | -$5.7M | |
| Interest Income Nonoperating | $1.8M | $2.1M | $2.3M | $2.9M | $2.7M | $3.3M | $2.3M | $2.4M | |
| Interest Expense Nonoperating | $3.2M | $3.1M | $2.7M | $0.00 | $5.4M | $8.1M | $8.1M | $7.9M | |
| Income Tax Expense Benefit | $0.00 | $2.0K | $0.00 | $0.00 | $2.0K | $0.00 | $2.0K | $5.0K | |
| General And Administrative Expense | $5.3M | $6.4M | $6.0M | $7.9M | $93.4M | $10.0M | $7.9M | $7.3M | |
| Revenues | $0.00 | $1.3M | $0.00 | $100.0K | $119.0K | $30.0K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$35.3M | -$28.7M | -$43.3M | -$43.9M | $1.86B | -$78.7M | -$51.8M | -$47.0M | |
| Income Taxes Paid Net | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $8.0M | $133.6M | $43.5M | $58.1M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $124.2M | $152.6M | $277.9M | $273.9M |
| Noncash Operating Lease Expense | $1.8M | $1.9M | $1.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$28.4M | -$125.3M | $4.1M | |
| Retained Earnings Accumulated Deficit | -$246.2M | -$106.1M | -$613.7M | |
| Property Plant And Equipment Net | $3.7M | $6.2M | $6.4M | |
| Prepaid Expense And Other Assets Current | $8.4M | $7.4M | $16.7M | |
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | |
| Other Assets Noncurrent | $4.4M | $6.8M | $3.2M | |
| Operating Lease Right Of Use Asset | $5.5M | $7.3M | $3.0M | |
| Operating Lease Liability Noncurrent | $4.1M | $6.5M | $1.1M | |
| Operating Lease Liability Current | $2.3M | $1.6M | $2.1M | |
| Liabilities Current | $33.8M | $40.7M | $56.3M | |
| Liabilities And Stockholders Equity | $146.5M | $180.8M | $307.9M | |
| Liabilities | $138.5M | $47.2M | $264.4M | |
| Common Stock Value | $1.0K | $1.0K | $5.0K | |
| Cash And Cash Equivalents At Carrying Value | $124.2M | $152.6M | $277.9M | |
| Assets Current | $132.8M | $160.4M | $295.4M | |
| Assets | $146.5M | $180.8M | $307.9M | |
| Accrued Liabilities Current | $25.5M | $29.9M | $43.3M | |
| Accounts Payable Current | $5.9M | $9.2M | $11.0M | |
| Long Term Debt Noncurrent | $100.6M | $0.00 | $207.0M | |
| Gain Loss On Sale Of Property Plant Equipment | -$12.0K | -$12.0K | -$3.0K | |
| Other Receivables Net Current | $177.0K | $197.0K | ||
| Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024Lease Agreement | $0.00 | $6.3M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $36.8M | $68.6M | $94.4M | $178.5M | $219.4M | $11.6M | $129.6M | -$24.8M | $15.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $153.1M | $186.6M | $216.5M | $196.3M | $226.9M | $252.5M | $337.3M | $192.5M | ||
| Noncash Operating Lease Expense | $434.0K | $465.0K | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $63.9M | -$25.4M | ||||||||
| Retained Earnings Accumulated Deficit | -$213.4M | -$178.1M | -$149.4M | -$58.3M | -$14.4M | |||||
| Property Plant And Equipment Net | $4.3M | $4.9M | $5.5M | $6.9M | $7.6M | |||||
| Prepaid Expense And Other Assets Current | $7.5M | $6.4M | $6.7M | $10.0M | $13.8M | |||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Other Assets Noncurrent | $5.7M | $6.8M | $6.8M | $6.7M | $6.7M | |||||
| Operating Lease Right Of Use Asset | $6.0M | $6.5M | $6.9M | $1.5M | $2.0M | |||||
| Operating Lease Liability Noncurrent | $4.7M | $5.3M | $5.9M | $0.00 | $0.00 | |||||
| Operating Lease Liability Current | $2.2M | $2.2M | $2.0M | $1.8M | $2.2M | |||||
| Liabilities Current | $36.0M | $38.9M | $43.6M | $44.1M | $39.1M | |||||
| Liabilities And Stockholders Equity | $177.5M | $212.1M | $242.6M | $222.6M | $258.4M | |||||
| Liabilities | $140.6M | $143.6M | $148.2M | $44.1M | $39.1M | |||||
| Common Stock Value | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |||||
| Cash And Cash Equivalents At Carrying Value | $153.1M | $186.6M | $216.5M | $196.3M | $226.9M | |||||
| Assets Current | $161.4M | $194.0M | $223.4M | $207.4M | $242.1M | |||||
| Assets | $177.5M | $212.1M | $242.6M | $222.6M | $258.4M | |||||
| Accrued Liabilities Current | $27.0M | $28.5M | $32.8M | $29.9M | $23.9M | |||||
| Accounts Payable Current | $6.8M | $8.3M | $8.9M | $12.4M | $13.0M | |||||
| Long Term Debt Noncurrent | $99.9M | $99.3M | $98.7M | $0.00 | $0.00 | |||||
| Gain Loss On Sale Of Property Plant Equipment | ||||||||||
| Other Receivables Net Current | $727.0K | $730.0K | $952.0K | $607.0K | ||||||
| Remeasurement Of Operating Lease Liability And Right Of Use Asset In Connection With2024Lease Agreement |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Depreciation Depletion And Amortization | $2.5M | $2.3M | $1.2M |
| Share Based Compensation | $11.1M | $58.5M | $24.8M |
| Proceeds From Stock Options Exercised | $1.6M | $71.7M | $2.3M |
| Payments To Acquire Property Plant And Equipment | $31.0K | $2.6M | $4.6M |
| Net Cash Provided By Used In Operating Activities | -$129.8M | -$194.4M | -$193.3M |
| Net Cash Provided By Used In Investing Activities | -$28.0K | -$2.6M | -$4.6M |
| Net Cash Provided By Used In Financing Activities | $101.4M | $71.7M | $202.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.4M | -$3.0M | $10.3M |
| Increase Decrease In Other Noncurrent Assets | $0.00 | $3.7M | $0.00 |
| Increase Decrease In Operating Lease Liability | -$1.6M | -$1.4M | -$1.9M |
| Increase Decrease In Due From Related Parties | -$23.0K | $23.0K | -$14.0K |
| Increase Decrease In Accrued Liabilities | -$4.4M | $35.9M | $26.1M |
| Increase Decrease In Accounts Receivable | -$200.0K | $185.0K | $535.0K |
| Increase Decrease In Accounts Payable | -$3.3M | $17.9M | $2.1M |
| Increase Decrease In Other Receivables | -$20.0K | -$566.0K | |
| Proceeds From Issuance Of Secured Debt | $100.0M | $0.00 | |
| Payments Of Debt Issuance Costs Secured Debt | $125.0K | $0.00 | |
| Proceeds From Issuance Of Private Placement | $0.00 | $200.0M | |
| Payments Of Private Placement Costs | $0.00 | $355.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Depreciation Depletion And Amortization | $582.0K | $662.0K | $675.0K | $760.0K | $475.0K | $360.0K | $304.0K | $295.0K |
| Share Based Compensation | $2.5M | $6.4M | ||||||
| Proceeds From Stock Options Exercised | $0.00 | $38.7M | ||||||
| Payments To Acquire Property Plant And Equipment | $21.0K | $1.1M | ||||||
| Net Cash Provided By Used In Operating Activities | -$35.9M | -$63.1M | ||||||
| Net Cash Provided By Used In Investing Activities | -$21.0K | -$1.1M | ||||||
| Net Cash Provided By Used In Financing Activities | $99.8M | $38.7M | ||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$730.0K | $2.4M | ||||||
| Increase Decrease In Other Noncurrent Assets | -$28.0K | $1.4M | ||||||
| Increase Decrease In Operating Lease Liability | -$171.0K | -$495.0K | ||||||
| Increase Decrease In Due From Related Parties | -$23.0K | $0.00 | ||||||
| Increase Decrease In Accrued Liabilities | $2.9M | $8.0M | ||||||
| Increase Decrease In Accounts Receivable | -$183.0K | $0.00 | ||||||
| Increase Decrease In Accounts Payable | -$353.0K | $4.1M | ||||||
| Increase Decrease In Other Receivables | $0.00 | $610.0K | ||||||
| Proceeds From Issuance Of Secured Debt | $100.0M | $0.00 | ||||||
| Payments Of Debt Issuance Costs Secured Debt | $125.0K | $0.00 | ||||||
| Proceeds From Issuance Of Private Placement | ||||||||
| Payments Of Private Placement Costs |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 15.5M | 14.8M | 11.8M |
| Weighted Average Number Of Diluted Shares Outstanding | 15.5M | 15.0M | 11.8M |
| Earnings Per Share Diluted | $-9.04 | $112.62 | $-20.48 |
| Earnings Per Share Basic | $-9.04 | $114.01 | $-20.48 |
| Preferred Stock Shares Authorized | 15.0M | 15.0M | 15.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Issued | 14.6M | 14.5M | 47.4M |
| Common Stock Shares Authorized | 120.0M | 120.0M | 120.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 14.6M | 14.5M | 47.4M |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 15.5M | 15.5M | 15.5M | 15.5M | 14.6M | 13.6M | 11.8M | 10.9M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 15.5M | 15.5M | 15.5M | 15.5M | 14.8M | 13.6M | 11.8M | 10.9M | ||
| Earnings Per Share Diluted | $-2.28 | $-1.85 | $-2.80 | $-2.84 | $125.48 | $-5.77 | $-4.39 | $-4.31 | ||
| Earnings Per Share Basic | $-2.28 | $-1.85 | $-2.80 | $-2.84 | $127.10 | $-5.77 | $-4.39 | $-4.31 | ||
| Preferred Stock Shares Authorized | 15.0M | 15.0M | 15.0M | 15.0M | 15.0M | |||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Common Stock Shares Issued | 14.5M | 14.5M | 14.5M | 14.5M | 14.5M | |||||
| Common Stock Shares Authorized | 120.0M | 120.0M | 120.0M | 120.0M | 120.0M | |||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Common Stock Shares Outstanding | 14.5M | 14.5M | 14.5M | 14.5M | 14.5M | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $11.1M | $58.5M | $24.8M |
| Stock Issued During Period Value Stock Options Exercised | $1.6M | $71.7M | $2.3M |
| Amortization Of Financing Costs And Discounts | $2.4M | $2.1M | $4.9M |
| Nonmonetary Transaction Gain Loss Recognized On Transfer | $0.00 | $2.02B | $0.00 |
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $519.0K | |
| Additional Paid In Capital | $254.2M | $239.7M | $657.2M |
| Interest Paid Net | $8.9M | $11.5M | $26.7M |
| Nonmonetary Transaction Gain Loss Recognized On Transfer Net | $0.00 | $2.00B | $0.00 |
| Stock Issued During Period Value New Issues | $16.0M | ||
| Other Noncash Income | $0.00 | $1.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.2M | $2.8M | $2.5M | $3.0M | $46.2M | $6.4M | $6.5M | $6.3M | $5.6M |
| Stock Issued During Period Value Stock Options Exercised | $352.0K | $31.3M | $40.4M | $21.0K | $854.0K | $356.0K | |||
| Amortization Of Financing Costs And Discounts | $533.0K | $1.2M | |||||||
| Nonmonetary Transaction Gain Loss Recognized On Transfer | $0.00 | $0.00 | $0.00 | $2.02B | $0.00 | $0.00 | |||
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $307.0K | |||||||
| Additional Paid In Capital | $250.2M | $246.7M | $243.9M | $236.7M | $233.8M | ||||
| Interest Paid Net | $1.3M | $6.9M | |||||||
| Nonmonetary Transaction Gain Loss Recognized On Transfer Net | |||||||||
| Stock Issued During Period Value New Issues | $16.0M | ||||||||
| Other Noncash Income |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.